Feasibility of combination allogeneic stem cell therapy for spinal cord injury

A case report

Thomas E. Ichim, Fabio Solano, Fabian Lara, Eugenia Paris, Federico Ugalde, Jorge Paz Rodriguez, Boris Minev, Vladimir Bogin, Famela Ramos, Erik J. Woods, Michael Murphy, Amit N. Patel, Robert J. Harman, Neil H. Riordan

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Cellular therapy for spinal cord injury (SCI) is overviewed focusing on bone marrow mononuclear cells, olfactory ensheathing cells, and mesenchymal stem cells. A case is made for the possibility of combining cell types, as well as for allogeneic use. We report the case of 29 year old male who suffered a crush fracture of the L1 vertebral body, lacking lower sensorimotor function, being a score A on the ASIA scale. Stem cell therapy comprised of intrathecal administration of allogeneic umbilical cord blood ex-vivo expanded CD34 and umbilical cord matrix MSC was performed 5 months, 8 months, and 14 months after injury. Cell administration was well tolerated with no adverse effects observed. Neuropathic pain subsided from intermittent 10/10 to once a week 3/10 VAS. Recovery of muscle, bowel and sexual function was noted, along with a decrease in ASIA score to "D". This case supports further investigation into allogeneic-based stem cell therapies for SCI.

Original languageEnglish
Article number30
JournalInternational Archives of Medicine
Volume3
Issue number1
DOIs
StatePublished - 2010

Fingerprint

Cell- and Tissue-Based Therapy
Spinal Cord Injuries
Stem Cells
Umbilical Cord
Neuralgia
Mesenchymal Stromal Cells
Fetal Blood
Bone Marrow Cells
Muscles
Wounds and Injuries
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ichim, T. E., Solano, F., Lara, F., Paris, E., Ugalde, F., Rodriguez, J. P., ... Riordan, N. H. (2010). Feasibility of combination allogeneic stem cell therapy for spinal cord injury: A case report. International Archives of Medicine, 3(1), [30]. https://doi.org/10.1186/1755-7682-3-30

Feasibility of combination allogeneic stem cell therapy for spinal cord injury : A case report. / Ichim, Thomas E.; Solano, Fabio; Lara, Fabian; Paris, Eugenia; Ugalde, Federico; Rodriguez, Jorge Paz; Minev, Boris; Bogin, Vladimir; Ramos, Famela; Woods, Erik J.; Murphy, Michael; Patel, Amit N.; Harman, Robert J.; Riordan, Neil H.

In: International Archives of Medicine, Vol. 3, No. 1, 30, 2010.

Research output: Contribution to journalArticle

Ichim, TE, Solano, F, Lara, F, Paris, E, Ugalde, F, Rodriguez, JP, Minev, B, Bogin, V, Ramos, F, Woods, EJ, Murphy, M, Patel, AN, Harman, RJ & Riordan, NH 2010, 'Feasibility of combination allogeneic stem cell therapy for spinal cord injury: A case report', International Archives of Medicine, vol. 3, no. 1, 30. https://doi.org/10.1186/1755-7682-3-30
Ichim, Thomas E. ; Solano, Fabio ; Lara, Fabian ; Paris, Eugenia ; Ugalde, Federico ; Rodriguez, Jorge Paz ; Minev, Boris ; Bogin, Vladimir ; Ramos, Famela ; Woods, Erik J. ; Murphy, Michael ; Patel, Amit N. ; Harman, Robert J. ; Riordan, Neil H. / Feasibility of combination allogeneic stem cell therapy for spinal cord injury : A case report. In: International Archives of Medicine. 2010 ; Vol. 3, No. 1.
@article{bfbaba33369b4dbdb40df9ccfa27fbb6,
title = "Feasibility of combination allogeneic stem cell therapy for spinal cord injury: A case report",
abstract = "Cellular therapy for spinal cord injury (SCI) is overviewed focusing on bone marrow mononuclear cells, olfactory ensheathing cells, and mesenchymal stem cells. A case is made for the possibility of combining cell types, as well as for allogeneic use. We report the case of 29 year old male who suffered a crush fracture of the L1 vertebral body, lacking lower sensorimotor function, being a score A on the ASIA scale. Stem cell therapy comprised of intrathecal administration of allogeneic umbilical cord blood ex-vivo expanded CD34 and umbilical cord matrix MSC was performed 5 months, 8 months, and 14 months after injury. Cell administration was well tolerated with no adverse effects observed. Neuropathic pain subsided from intermittent 10/10 to once a week 3/10 VAS. Recovery of muscle, bowel and sexual function was noted, along with a decrease in ASIA score to {"}D{"}. This case supports further investigation into allogeneic-based stem cell therapies for SCI.",
author = "Ichim, {Thomas E.} and Fabio Solano and Fabian Lara and Eugenia Paris and Federico Ugalde and Rodriguez, {Jorge Paz} and Boris Minev and Vladimir Bogin and Famela Ramos and Woods, {Erik J.} and Michael Murphy and Patel, {Amit N.} and Harman, {Robert J.} and Riordan, {Neil H.}",
year = "2010",
doi = "10.1186/1755-7682-3-30",
language = "English",
volume = "3",
journal = "International Archives of Medicine",
issn = "1755-7682",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Feasibility of combination allogeneic stem cell therapy for spinal cord injury

T2 - A case report

AU - Ichim, Thomas E.

AU - Solano, Fabio

AU - Lara, Fabian

AU - Paris, Eugenia

AU - Ugalde, Federico

AU - Rodriguez, Jorge Paz

AU - Minev, Boris

AU - Bogin, Vladimir

AU - Ramos, Famela

AU - Woods, Erik J.

AU - Murphy, Michael

AU - Patel, Amit N.

AU - Harman, Robert J.

AU - Riordan, Neil H.

PY - 2010

Y1 - 2010

N2 - Cellular therapy for spinal cord injury (SCI) is overviewed focusing on bone marrow mononuclear cells, olfactory ensheathing cells, and mesenchymal stem cells. A case is made for the possibility of combining cell types, as well as for allogeneic use. We report the case of 29 year old male who suffered a crush fracture of the L1 vertebral body, lacking lower sensorimotor function, being a score A on the ASIA scale. Stem cell therapy comprised of intrathecal administration of allogeneic umbilical cord blood ex-vivo expanded CD34 and umbilical cord matrix MSC was performed 5 months, 8 months, and 14 months after injury. Cell administration was well tolerated with no adverse effects observed. Neuropathic pain subsided from intermittent 10/10 to once a week 3/10 VAS. Recovery of muscle, bowel and sexual function was noted, along with a decrease in ASIA score to "D". This case supports further investigation into allogeneic-based stem cell therapies for SCI.

AB - Cellular therapy for spinal cord injury (SCI) is overviewed focusing on bone marrow mononuclear cells, olfactory ensheathing cells, and mesenchymal stem cells. A case is made for the possibility of combining cell types, as well as for allogeneic use. We report the case of 29 year old male who suffered a crush fracture of the L1 vertebral body, lacking lower sensorimotor function, being a score A on the ASIA scale. Stem cell therapy comprised of intrathecal administration of allogeneic umbilical cord blood ex-vivo expanded CD34 and umbilical cord matrix MSC was performed 5 months, 8 months, and 14 months after injury. Cell administration was well tolerated with no adverse effects observed. Neuropathic pain subsided from intermittent 10/10 to once a week 3/10 VAS. Recovery of muscle, bowel and sexual function was noted, along with a decrease in ASIA score to "D". This case supports further investigation into allogeneic-based stem cell therapies for SCI.

UR - http://www.scopus.com/inward/record.url?scp=78149352217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149352217&partnerID=8YFLogxK

U2 - 10.1186/1755-7682-3-30

DO - 10.1186/1755-7682-3-30

M3 - Article

VL - 3

JO - International Archives of Medicine

JF - International Archives of Medicine

SN - 1755-7682

IS - 1

M1 - 30

ER -